Arvinas Estrogen Receptor, Inc.
2 clinical trials · Sponsor
◉ Watch Arvinas Estrogen Receptor, Inc.
| Record | Firm | Date |
|---|---|---|
| ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (NCT05501769) | Arvinas Estrogen Receptor, Inc. | 2022-09-08 |
| A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (NCT04072952) | Arvinas Estrogen Receptor, Inc. | 2019-08-05 |
Track Arvinas Estrogen Receptor, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.